Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2017

Open Access 01-12-2017 | Research article

p53 expression in patients with ulcerative colitis - associated with dysplasia and carcinoma: a systematic meta-analysis

Authors: Xiaohong Lu, Yuanjie Yu, Shiyun Tan

Published in: BMC Gastroenterology | Issue 1/2017

Login to get access

Abstract

Background

Tumor suppressor gene p53 expression has been reported in patients with ulcerative colitis (UC). However, the correlation between p53 expression and UC remains controversial. The aim of this meta-analysis was to investigate the association between p53 expression and different pathological types of UC.

Methods

Publications were searched in the PubMed, Embase, EBSCO, Wangfang, and CNKI databases. The overall odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were summarized in this study.

Results

Final 19 papers were identified in this meta-analysis, including 1068 patients with UC and 130 normal tissue samples. Immunohistochemical p53 expression was significantly higher in UC without dysplasia and carcinoma (UC group) compared to normal tissue samples (OR = 3.14, P = 0.001), higher in UC with dysplasia than in UC group (OR = 10.76, P < 0.001), and higher in UC with colorectal cancer (CRC) than in UC with dysplasia (OR = 1.69, P = 0.035). Subgroup analysis of ethnicity (UC group vs. normal tissues) showed that p53 expression was correlated with UC in Asians, but not in Caucasians. When UC with dysplasia was compared to UC group, p53 expression was linked to UC with dysplasia among both Asians and Caucasians. When UC-CRC was compared to UC with dysplasia, p53 expression was not associated with UC-CRC in both Caucasians and Asians.

Conclusions

p53 expression was closely associated with UC-CRC development. p53 expression showed different ethnic characteristics among different pathological types of UC.
Appendix
Available only for authorised users
Literature
1.
Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–63.CrossRefPubMed
2.
Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111–32.PubMedPubMedCentral
3.
Choi JK, Kim DW, Shin SY, Park EC, Kang JG. Effect of ulcerative colitis on incidence of colorectal cancer: results from the Nationwide population-based cohort study (2003–2013). J Cancer. 2016;7(6):681–6.CrossRefPubMedPubMedCentral
4.
Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–51.CrossRefPubMed
5.
Ventham NT, Kennedy NA, Adams AT, Kalla R, Heath S, O'Leary KR, Drummond H, Consortium IB, Consortium IC, Wilson DC, Gut IG, Nimmo ER, Satsangi J. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nat Commun. 2016;7:13507.CrossRefPubMedPubMedCentral
6.
Sun M, Zhang L, Shi S. Associations between NRAMP1 polymorphisms and susceptibility to ulcerative colitis/Crohn's disease: a meta-analysis. Immunol Investig. 2016;45(3):255–70.CrossRef
7.
Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagace C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246–52.CrossRefPubMedPubMedCentral
8.
Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollon F, Hauser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7(1):1–33.CrossRefPubMed
9.
McBride OW, Merry D, Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U S A. 1986;83(1):130–4.CrossRefPubMedPubMedCentral
10.
11.
Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg. 1998;85(11):1460–7.CrossRefPubMed
12.
Davelaar AL, Calpe S, Lau L, Timmer MR, Visser M, Ten Kate FJ, Parikh KB, Meijer SL, Bergman JJ, Fockens P and Krishnadath KK. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: a prospective follow-up study. Genes Chromosomes Cancer 2015; 54(2):82–90.
13.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49–53.CrossRefPubMed
14.
Kawamata S, Matsuzaki K, Murata M, Seki T, Matsuoka K, Iwao Y, Hibi T, Okazaki K. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis. 2011;17(3):683–95.CrossRefPubMed
15.
Klump B, Holzmann K, Kuhn A, Borchard F, Sarbia M, Gregor M, Porschen R. Distribution of cell populations with DNA aneuploidy and p53 protein expression in ulcerative colitis. Eur J Gastroenterol Hepatol. 1997;9(8):789–94.CrossRefPubMed
16.
Du L, Kim JJ, Shen J, Chen B, Dai NKRAS. TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. Oncotarget. 2017;8(13):22175–86.PubMedPubMedCentral
17.
Li J, Lai MD, Huang Q. Alterations of p53 gene and microsatellite instability in ulcerative colitis and ulcerative colitis-associated colorectal cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004;33(2):108–14.PubMed
18.
Ding Y, Yang Q, Wang B, Ye G, Tong X. The correlation of MGMT promoter methylation and Clinicopathological features in gastric cancer: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0165509.CrossRefPubMedPubMedCentral
19.
Zintzaras E, Ioannidis JPHEGESMA. Genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed
20.
Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.CrossRefPubMed
21.
22.
Yoshida T, Matsumoto N, Mikami T, Okayasu I. Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours. Br J Cancer. 2004;91(6):1081–8.PubMedPubMedCentral
23.
Bruwer M, Schmid KW, Senninger N, Schurmann G. Immunohistochemical expression of P53 and oncogenes in ulcerative colitis-associated colorectal carcinoma. World J Surg. 2002;26(3):390–6.CrossRefPubMed
24.
Ishitsuka T, Kashiwagi H, Konishi F. Microsatellite instability in inflamed and neoplastic epithelium in ulcerative colitis. J Clin Pathol. 2001;54(7):526–32.CrossRefPubMedPubMedCentral
25.
Hirota Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N. pS2 expression as a possible diagnostic marker of colorectal carcinoma in ulcerative colitis. Oncol Rep. 2000;7(2):233–9.PubMed
26.
Sato A and MacHinami R. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol Int 1999; 49(10):858–868.
27.
Fogt F, Zhuang Z, Poremba C, Dockhorn-Dworniczak B, Vortmeyer A. Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. Oncol Rep. 1998;5(2):477–80.PubMed
28.
Harpaz N, Peck AL, Yin J, Fiel I, Hontanosas M, Tong TR, Laurin JN, Abraham JM, Greenwald BD, Meltzer SJ. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol. 1994;25(10):1069–74.CrossRefPubMed
29.
Taylor HW, Boyle M, Smith SC, Bustin S, Williams NS. Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg. 1993;80(4):442–4.CrossRefPubMed
30.
Wang H, Yan LI, Zhang WW. The expression of P53,K-ras and hMSH2 in ulcerative colitis-associated colorectal cancer. Chinese Journal of Digestion. 2005;
31.
Wang YY, QiU B, Yu J, Li XR, Tian YL, Zhang PY, Shi CL, Chen XY. The expression of CD15, myeloperoxidase, P53 and Rb in ulcerative colitis, adenoma, and colorectal cancer. Chin J. Dig. 2008;28(3):194–6.
32.
Shigaki K, Mitomi H, Fujimori T, Ichikawa K, Tomita S, Imura J, Fujii S, Itabashi M, Kameoka S, Sahara R, Takenoshita S. Immunohistochemical analysis of chromogranin a and p53 expressions in ulcerative colitis-associated neoplasia: neuroendocrine differentiation as an early event in the colitis-neoplasia sequence. Hum Pathol. 2013;44(11):2393–9.CrossRefPubMed
33.
Wohl P, Hucl T, Drastich P, Kamenar D, Spicak J, Honsova E, Sticova E, Lodererova A, Matous J, Hill M, Wohl P, Kucera M. Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. World J Gastroenterol. 2013;19(14):2234–41.CrossRefPubMedPubMedCentral
34.
Scarpa M, Cardin R, Bortolami M, Kotsafti A, Scarpa MC, Pozza A, Maran G, Picciocchi M, Ruffolo C, D'Inca R, Sturniolo GC, Castagliuolo I, Castoro C, Angriman I. Mucosal immune environment in colonic carcinogenesis: CD80 expression is associated to oxidative DNA damage and TLR4-NFkappaB signalling. Eur J Cancer. 2013;49(1):254–63.CrossRefPubMed
35.
Gushima M, Hirahashi M, Matsumoto T, Fujita K, Ohuchida K, Oda Y, Yao T, Iida M, Tsuneyoshi M. Expression of activation-induced cytidine deaminase in ulcerative colitis-associated carcinogenesis. Histopathology. 2011;59(3):460–9.CrossRefPubMed
36.
Tanaka H, Fukui H, Fujii S, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, Imura J, Yasuda Y, Chiba T, Fujimori T. Immunohistochemical analysis of REG Ialpha expression in ulcerative colitis-associated neoplastic lesions. Digestion. 2011;83(3):204–9.CrossRefPubMed
37.
Alkim C, Savas B, Ensari A, Alkim H, Dagli U, Parlak E, Ulker A, Sahin B. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig Dis Sci. 2009;54(9):1979–84.CrossRefPubMed
38.
Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M. Overexpression of p53 protein in human tumors. Med Mol Morphol. 2012;45(3):115–23.CrossRefPubMed
39.
Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994;172(1):5–12.CrossRefPubMed
40.
Alaizari NA, Tarakji B, Al-Maweri SA, Al-Shamiri HM, Darwish S, Baba F. p53 expression in pleomorphic adenoma of salivary glands: A systematic review and meta-analysis. Arch Oral Biol. 2015;60(9):1437–41.CrossRefPubMed
41.
Mitchell S, Mayer E, Patel A. Expression of p53 in upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8(9):516–22.CrossRefPubMed
42.
Junior AT, de Abreu Alves F, Pinto CA, Carvalho AL, Kowalski LP, Lopes MA. Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas. Oral Oncol. 2003;39(5):521–30.CrossRefPubMed
43.
Laurent C, Svrcek M, Flejou JF, Chenard MP, Duclos B, Freund JN, Reimund JM. Immunohistochemical expression of CDX2, beta-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer. Inflamm Bowel Dis. 2011;17(1):232–40.CrossRefPubMed
44.
Romero M, Artigiani R, Costa H, Oshima CT, Miszputen S, Franco M. Evaluation of the immunoexpression of COX-1, COX-2 and p53 in Crohn's disease. Arq Gastroenterol. 2008;45(4):295–300.CrossRefPubMed
Metadata
Title
p53 expression in patients with ulcerative colitis - associated with dysplasia and carcinoma: a systematic meta-analysis
Authors
Xiaohong Lu
Yuanjie Yu
Shiyun Tan
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2017
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-017-0665-y

Other articles of this Issue 1/2017

BMC Gastroenterology 1/2017 Go to the issue

Research article

Systematic review with network meta-analysis: dual therapy for high-risk bleeding peptic ulcers

Research article

First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis

Research article

“Non alcoholic fatty liver disease and eNOS dysfunction in humans”

Research article

Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: retrospective analysis of a multicenter study

Research article

Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease — a nationwide cohort study

Research article

Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits